NASDAQ · RAPT
RAPT Therapeutics, Inc.
$58.01+$0.00 (0.0%)
RAPT Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.03% below the high.
Loading market information…
NASDAQ · OCGN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ocugen, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ocugen, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 9, 2025 |
| -$0.05+16.67% vs estimate |
| $1.48M |
| Q4 2024 | Mar 5, 2025 | -$0.050.0% vs estimate | $764.00K+91.0% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.050.0% vs estimate | $1.14M+184.0% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$58.01+$0.00 (0.0%)
RAPT Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.03% below the high.
$18.95+$1.07 (+5.98%)
Omeros Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.78% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$1.48-$0.01 (-0.34%)
Lexicon Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$3.77+$0.02 (+0.53%)
Fulcrum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.05% below the high.
$1.03-$0.01 (-0.96%)
Lineage Cell Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
$1.49-$0.13 (-8.02%)
ADC Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.08% below the high.
